Premium
Sequential treatment of recurrent mesenteric desmoid tumor
Author(s) -
Bauernhofer Thomas,
Stöger Herbert,
Schmid Marianne,
Smola Michael,
GürtlLackner Barbara,
Höfler Gerald,
Ranner Gerhard,
Reisinger Emil,
Samonigg Hellmut
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960315)77:6<1061::aid-cncr9>3.0.co;2-k
Subject(s) - medicine , tamoxifen , goserelin , medroxyprogesterone acetate , urology , antiestrogen , chemotherapy , surgery , gastroenterology , cancer , estrogen , breast cancer
BACKGROUND The optimal management of inoperable desmoid tumors is still unclear. We report a 26 year‐old female patient with familial adenomatous polyposis suffering from a recurrent inoperable intraabdominal desmoid tumor and its sequential treatment. METHODS Treatment strategies included low‐dose tamoxifen (30 mg orally per day), high‐dose tamoxifen (90 mg orally per day), and a subsequent combination of goserelin acetate (3.6 mg subcutaneously once every four weeks) plus low‐dose tamoxifen, medroxyprogesterone acetate (1000 mg orally per day) and interferon gamma (3 Mio IU subcutaneously 3 times a week). RESULTS The combination of goserelin acetate and low‐dose tamoxifen resulted in a decrease in tumor size and a complete relief of symptoms for 17 months. Thereafter the tumor progressed and again growth was stopped with interferon gamma therapy for another 6 months. All other treatment modalities had no effect. CONCLUSIONS This study demonstrates long‐term regression of a desmoid tumor with combined endocrine therapy using goserelin acetate plus tamoxifen. Tumor progression after 17 months was again stopped by a combination of interferon‐gamma and goserelin acetate. Cancer 1996;77:1061‐5.